ABOUT US
MISSION: Syracuse Biolabs (SBL) is focused on commercial development of early stage biochemical and medical based technologies, including but not limited to diagnostics, biosensing, therapeutics, medical devices, kit chemistry/reagents, liquid biopsies and healthcare products.
OVERVIEW: Syracuse Biolabs (SBL) is a biotechnology firm focused on meeting its corporate mission by leveraging internal expertise, as well as partnering with academic and contract laboratories to drive novel medical and biotechnology from early stage funding through commercialization. The executive and scientific team at SBL have 20 years of experience funding and commercializing projects through seed, state, and federal funding mechanisms (i.e. NIH, AFRL, HSARPA, and DOD).
While SBL purses internal R&D projects, we also conduct external research with partners interested in developing medical and biochem technology. Located in the CNY Biotech accelerator, SBL staff has access to state-of-the art research facilities and core equipment needed to advance innovative medical and biotechnological products from proof-of-concept to commercialization. SBL has the scientific track record, administrative and research infrastructure to accommodate a broad range commercial science.
While SBL purses internal R&D projects, we also conduct external research with partners interested in developing medical and biochem technology. Located in the CNY Biotech accelerator, SBL staff has access to state-of-the art research facilities and core equipment needed to advance innovative medical and biotechnological products from proof-of-concept to commercialization. SBL has the scientific track record, administrative and research infrastructure to accommodate a broad range commercial science.
MANAGEMENT
PRESIDENT: Dr. Mark McPike, Ph.D.
